Bax Induction Activates Apoptotic Cascade via Mitochondrial Cytochrome c Release and Bax Overexpression Enhances Apoptosis Induced by Chemotherapeutic Agents in DLD-1 Colon Cancer Cells

Tohru Kobayashi,1, 3, 4 Hidehiko Sawa,1, 3 Jun Morikawa,1 Wei Zhang2 and Hiroshi Shiku1

The Second Department of Internal Medicine, Mie University School of Medicine, 2-174 Edobashi, Tsu, 514-8507 and The Department of Pathology, Division of Pathology and Lab Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA

Cancer cells express different levels of apoptosis-promoting Bax protein. The present study evaluated whether induction of Bax initiates apoptosis and whether Bax overexpression enhances apoptosis induced by several chemotherapeutic agents in DLD-1 colon cancer cells, which originally express a high level of endogenous Bax protein and a low level of Bel-2 protein. To investigate these two points, parental DLD-1 cells were transfected with the Tet-On Bax induction system (pTet-On and pTRE-Bax plasmids), and stable transduced cells were obtained. Induction of Bax by the Tet-On system initiated cytochrome c release from mitochondria, caspase-3 activation, and apoptosis to some extent in DLD-1 cells. Apoptosis induced by a chemotherapeutic agent, 5-fluorouracil, mitomycin C, paclitaxel, doxorubicin, or cisplatin, was enhanced by Bax overexpression. These findings suggest that Bax-overexpression-based gene therapy combined with chemotherapy would be effective in the treatment of colon cancer.

Key words: Bax — Tet-On system — DLD-1 colon cancer cells — Mitochondrial cytochrome c release — Chemotherapeutic agents

Doses of chemotherapeutic agents are limited by various toxicities. Combined therapies with different mechanisms may be a more effective approach to improve the outcome of chemotherapy and bring survival benefit. Anti-cancer effects induced by various chemotherapeutic agents are considered to be based on induction of apoptosis and are mediated through a final common pathway; activation of caspase-3 and subsequent DNA fragmentation.1, 4 With the aim of enhancing chemotherapeutic agent-induced apoptosis, we have focused on the function of the apoptosis-promoting gene, Bax. It has been reported that Bax induction alone induces apoptosis in Jurkat cells,5 which have a Bax gene mutation.6 Strobel et al. have reported that Bax overexpression enhances apoptosis induced by paclitaxel, vincristine and doxorubicin, but not by carboplatin, etoposide or hydroxyurea in ovarian cancer cells.7 Wagener et al. have reported that Bax induction alone does not induce apoptosis of breast cancer cells, but sensitizes the cells to epirubicin-induced apoptosis.8 We have shown that Bax overexpression sensitizes K562 erythroid leukemia cells to apoptosis induced by β-D-arabinofuranoside, doxorubicin, and SN-38 (irinotecan), but not to etoposide.9 These findings suggest that the effects of Bax overexpression to induce apoptosis and to enhance chemotherapeutic agent-induced apoptosis are different among different cell lines and chemotherapeutic agents.

Patients with advanced colorectal cancer are often treated with 5-fluorouracil-based regimens; however, the responses are partial and no survival benefit has been demonstrated.10 Mutation of the tumor suppressor gene p53 is frequent in colon cancer cells,11 and in a clinical treatment of lung cancer, wild-type p53 gene delivery to cancer cells has been performed.12 Bax gene is considered to be one of the downstream genes regulated by p53, and the promoter of Bax has a p53 binding domain.13 Bax gene mutation has been reported in hereditary non-polyposis colorectal cancer, but not in other types of colorectal cancer.14–16 In addition, there is no report about the sensitization of colon cancer cells to chemotherapeutic agents by Bax overexpression. In the present study, we examined whether Bax induction alone initiates apoptosis in DLD-1 colon cancer cells and whether Bax overexpression sensitizes DLD-1 colon cancer cells to apoptosis induced by chemotherapeutic agents, 5-fluorouracil, mitomycin C, paclitaxel, doxorubicin, and cisplatin.

MATERIALS AND METHODS

Cell culture DLD-1 cells were obtained from the American Type Culture Collection (Rockville, MD), and were maintained in RPMI-1640 medium supplemented with 10% Tet-system approved fetal calf serum (Clontech, Palo Alto, CA) under air containing 5% CO2 in an incubator at 37°C.

DNA transfection pTet-On regulator plasmid (pTet-On)17 and pTRE response plasmid (pTRE)18 were purchased
from Clontech. Bax gene was inserted to the EcoRI cloning site of pTRE (pTRE-Bax). pTet-On was transfected into DLD-1 cells using Lipofectamine (Life Technologies, Rockville, MD) and stable transfectants (DLD-1-pTet-On) were selected in RPMI-1640 medium containing 0.8 mg/ml G418 (Life Technologies) for more than 4 weeks. pTRE-Bax and pTK-Hyg, which contains hygromycin-resistance gene, were combined in a ratio of twenty to one and ethanol-precipitated. DLD-1-pTet-On cells were transfected with pTRE-Bax/pTK-Hyg, and stable transfectants were selected in RPMI-1640 medium containing 0.4 mg/ml hygromycin (Sigma, St. Louis, MO).

**Western blotting** Total cellular protein was extracted with NP-40-based lysis buffer and analyzed by sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) as described previously. After having been transferred to an Immobilon membrane (Millipore, Bedford, MA), the proteins were incubated overnight with antibodies against Bax (N-20) (Santa Cruz Biotechnology, Santa Cruz, CA), caspase 3 (Santa Cruz), cytochrome c (Pharmingen, San Diego, CA), Bcl-2 (DAKO A/S, Denmark), Bcl-X (Santa Cruz) and β-actin (AC-15) (Sigma). The levels of protein were analyzed using the enhanced chemiluminescence system (Amersham Pharmacia Biotech, Little Chalfont, Buckinghamshire, England) according to the manufacturer’s instructions. To detect the release of cytochrome c from mitochondria, cytosol fraction was extracted with mannitol-based lysis buffer and the mitochondria-containing fraction was extracted from the pellet with NP-40-based lysis buffer.

**Flow cytometry** To quantitate apoptotic cells, an apoptosis detection system (fluorescein) (Promega, Madison, WI) was used according to the manufacturer’s instructions. This system measures the fragmented DNA of apoptotic cells and is called terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) assay.

---

**Fig. 1.** DLD-1 cells stably transfected with the Bax-inducible Tet-On system, DLD-1-pTet-On/pTRE-Bax (DLD-1-Bax) cells, were used. A. TUNEL-positive cells appeared 6–12 h after addition of doxycycline, and maximum levels were detected at 36–48 h. Data are presented as the average of three independent experiments with standard deviations. B. Flow cytometry of TUNEL assay before and 48 h after addition of 1 µg/ml doxycycline.

**Fig. 2.** A. Western blotting of whole cell fraction extracted from DLD-1-Bax cells. Caspase-3 activation was observed from 36 h after addition of doxycycline. Bcl-2 was not detected at any time point and Bcl-XL was slightly induced 48 h after addition of doxycycline. B. Western blotting of cytosol fraction and mitochondria-containing fraction. Bax induction was observed in both cytosol and mitochondria-containing fraction. Increase of cytochrome c in cytosol fraction was observed 24 h after addition of doxycycline and decrease of cytochrome c in mitochondria-containing fraction was observed 36 h after addition of doxycycline.
RESULTS

Establishment of a stable cell line transfected with Tet-On system  To evaluate apoptosis induced by Bax overexpression in DLD-1 colon cancer in the absence of any cytotoxic signals, a stable cell line (mixed population of stable transfectants), DLD-1-pTet-On/pTRE-Bax/pTK-Hyg (DLD-1-Bax), was established.

Detection of apoptosis and western blotting after induction of Bax  TUNEL-positive cells increased after exposure to 1 µg/ml doxycycline and the highest percentages of TUNEL-positive cells were observed at the 36 h and 48 h time points (Fig. 1). Continuous exposure of these cells to 1 µg/ml doxycycline did not result in total cell death but resulted in establishment of Bax-overexpressing stable cell lines (data not shown). Western blotting using whole cell fraction revealed Bax induction (Fig. 2A) and caspase-3 activation (Fig. 2A) 36 h after exposure to doxycycline. Bcl-2 protein expression did not show any change and Bcl-XL was slightly elevated 36–48 h after exposure to doxycycline. Bcl-2 protein expression did not show any change and Bcl-XL was slightly elevated 36–48 h after exposure to doxycycline (Fig. 2A). Bax induction was observed in both cytosol and mitochondria-containing...
fractions (Fig. 2B). Cytochrome c release from mitochondria to cytosol was detected 36 h after exposure to doxycycline.

**Apoptosis induced by chemotherapeutic agents** Concentrations of anticancer agents used in this study are based on previous reports,7,9 ten times higher concentrations than the maximum plasma levels in clinical use and preliminary dose-setting experiments. DLD-1-Bax cells with or without Bax induction were treated with a chemotherapeutic agent, 25 µg/ml 5-fluorouracil, 2 µg/ml mitomycin C, 1 µg/ml paclitaxel, 1 µg/ml doxorubicin, or 10 µg/ml cisplatin, and apoptosis was evaluated by TUNEL assay (Fig. 3). In the preliminary experiments, DLD-1-Bax cells were incubated with 1 µg/ml doxycycline 6 h or 24 h before addition of chemotherapeutic agents, but there was no difference in apoptosis between 6 h and 24 h. Therefore, 1 µg/ml doxycycline was added 6 h before chemotherapeutic agent treatments. Four or five days after treatment with chemotherapeutic agents, more-than-additive numbers of apoptotic cells were observed in chemotherapeutic agent-treated DLD-1-Bax cells with Bax overexpression compared with those lacking Bax induction (Fig. 3).

**DISCUSSION**

It has been reported that Bax induction alone induces apoptosis in Jurkat cells,5 but Jurkat cells have a Bax gene mutation and do not express Bax protein.6 Cancer cells express different levels of proapoptotic Bax protein.6 The present study demonstrated that Bax induction alone initiated cytochrome c release from mitochondria, activation of caspase 3 and apoptosis to some extent in DLD-1 cells, which originally express a high level of proapoptotic Bax protein. Recently, a pathway between Bax induction and caspase-3 activation has been reported. Overexpressed Bax moves to mitochondria21 and induces cytochrome c release from mitochondria.20,22 Released cytochrome c binds to Apaf-1 and caspase-9, and the complex subsequently activates caspase-3,23,24 The release of cytochrome c occurs independently of changes of mitochondrial membrane potential20,25 and caspase activation20,22 and is inhibited by Bcl-XL.20,26 In the present study, after Bax induction, Bcl-XL, one of the antagonists of Bax, was slightly elevated, which might alleviate the Bax-induced apoptosis in DLD-1 cells. Cytochrome c release was observed at the same time as caspase-3 activation, supporting the sequential activation of the apoptotic cascade already described.20–24 We have recently shown that Bax overexpression sensitizes KATO-III gastric cancer cells to chemotherapeutic agent-induced apoptosis through enhancing the release of cytochrome c from mitochondria.27 In the present study, apoptosis induced by all chemotherapeutic agents tested was enhanced by Bax overexpression, suggesting that the target of Bax overexpression is the final common pathway. It has been reported that dimerization of mitochondrial Bax is also associated with increased drug response in Bax-transfected human head and neck squamous cancer cells.28 On the other hand, Strobel et al. reported that intracellular accumulation of paclitaxel was enhanced by Bax overexpression.29 We assume that enhancement of chemotherapeutic agent-induced apoptosis by Bax overexpression is mediated both by the common pathway of mitochondrial cytochrome c release and by the specific mechanism of each chemotherapeutic agent.

It has been reported that wild-type p53 does not induce apoptosis in wild-type p53-bearing cancer cells. The present study showed that overexpression of Bax itself induced apoptosis in DLD-1 colon cancer cells to some extent, and that Bax overexpression sensitizes DLD-1 cells to chemotherapeutic agent-induced apoptosis. In the case of 5-fluorouracil, which is a key drug in the treatment of colorectal cancer,10 enhancement of apoptosis by Bax was observed at an early time. Thus, Bax overexpression-based gene therapy may be an effective approach for the treatment of colon cancer, in combination with chemotherapy.30

**ACKNOWLEDGMENTS**

This study was supported in part by grants (No. 11140229 and No. 10670944) from the Ministry of Education, Science, Sports and Culture, Japan.

(Received July 28, 2000/Revised September 18, 2000/Accepted September 25, 2000)

**REFERENCES**

1) Mukae, N., Enari, M., Sakahira, H., Fukuda, Y., Inazawa, J., Toh, H. and Nagata, S. Molecular cloning and characterization of human caspase-activated DNase. Proc Natl Acad Sci USA, 95, 9121–9128 (1998).
2) Enari, M., Sakahira, H., Yokoyama, H., Okawa, K., Iwamatsu, A. and Nagata, S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature, 391, 43–50 (1998).
3) Sakahira, H., Enari, M. and Nagata, S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature, 391, 96–99 (1998).
4) Khwaja, A. and Tatton, L. Caspase-mediated proteolysis and activation of protein kinase C8 plays a central role in neutrophil apoptosis. Blood, 94, 291–301 (1999).
5) Xiang, J., Chao, D. T. and Korsmeyer, S. J. BAX-induced cell death may not require interleukin 1β-converting
enzyme-like proteases. *Proc. Natl. Acad. Sci. USA*, **93**, 14559–14563 (1996).

6) Meijerink, J. P. P., Mensink, E. J. B. M., Wang, K., Sedlak, T. W., Sloetjes, A. W., de Witte, T., Waksman, G. and Korsmeyer, S. J. Hematopoietic malignancies demonstrated loss-of-function mutation of BAX. *Blood*, **91**, 2991–2997 (1998).

7) Strobelt, T., Swanson, L., Korsmeyer, S. and Cannistra, S. A. BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. *Proc. Natl. Acad. Sci. USA*, **93**, 14094–14099 (1996).

8) Wagener, C., Bargou, R. C., Daniel, P. T., Bommert, K., Mapara, M. Y., Royer, H. D. and Dorken, B. Induction of the death-promoting gene bax-α sensitizes cultured breast-cancer cells to drug-induced apoptosis. *Int. J. Cancer*, **67**, 138–141 (1996).

9) Kobayashi, T., Ruan, S., Clodi, K., Kliche, K.-O., Shiku, H., Andreeff, M. and Zhang, W. Overexpression of Bax gene sensitizes K562 erythroleukemia cells to apoptosis induced by selective chemotherapeutic agents. *Oncogene*, **16**, 1578–1591 (1998).

10) Cohen, A. M., Minsky, B. D. and Schilsky, R. L. Cancer of the colon. In “Cancer Principles & Practice of Oncology,” 4th Ed., ed. V. T. DeVita, S. Hellman and S. A. Rosenberg, pp. 1144–1197 (1997). Lippincott-Raven Publ., Philadelphia.

11) Marx, J. New colon cancer gene discovered. *Science*, **260**, 751–752 (1992).

12) Roth, J. A., Nguyen, D., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., Ferson, D. Z., Hong, W. K., Komaki, R., Lee, J. J., Nesbitt, J. C., Pisters, K. M., Putnam, J. B., Schea, R., Shin, D. M., Walsh, G. L., Dolormente, M. M., Han, C. I., Martin, F. D., Yen, N., Xu, K., Stephens, L. C., McDonnell, T. J., Mukhopadhyay, T. and Cai, D. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. *Nat. Med.*, **2**, 985–991 (1996).

13) Miyashita, T. and Reed, J. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. *Cell*, **80**, 293–299 (1995).

14) Rampino, N., Yamamoto, H., Ionov, Y., Li, Y., Sawai, H., Reed, J. C. and Peroucho, M. Somatic frame-shift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. *Science*, **275**, 967–969 (1997).

15) Yagi, O. K., Akiyama, Y., Nomizu, T., Iwama, T., Endo, M. and Yuasa, Y. Proapoptotic gene BAX is frequently mutated in hereditary nonpolyposis colorectal cancers but not in adenomas. *Gastroenterology*, **114**, 268–274 (1998).

16) Yamamoto, H., Sawai, H., Weber, T. K., Rodriguez-Bigas, M. A. and Peroucho, M. Somatic frame-shift mutations in DNA mismatch repair and proapoptosis genes in hereditary nonpolyposis colorectal cancer. *Cancer Res.*, **58**, 997–1003 (1998).

17) Gossen, M., Freundlieb, S., Bender, G., Muller, G., Hillen, W. and Bujard, H. Transcriptional activation by tetracyclines in mammalian cells. *Science*, **268**, 1766–1769 (1995).

18) Gossen, M and Bujard, H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. *Proc. Natl. Acad. Sci. USA*, **89**, 5547–5551 (1992).

19) Zhang, W., Guo, X.-Y., Hu, G.-Y., Liu, W.-B., Bray, J. W. and Deisseroth, A. B. A temperature-sensitive mutant of human p53. *EMBO J.*, **13**, 2535–2544 (1994).

20) Finucane, D. M., Bossy-Wetzel, E., Waterhouse, N. J., Cotter, T. G. and Green, D. R. Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibited by Bcl-XL. *J. Biol. Chem.*, **274**, 2225–2233 (1999).

21) Wolter, K. G., Hsu, Y.-T., Smith, C. L., Nechushtan, A., Xi, X.-G., Richard, J. and Youle, R. J. Movement of Bax from the cytosol to mitochondria during apoptosis. *J. Cell Biol.*, **139**, 1281–1292 (1997).

22) Jurgensmeier, J. M., Xie, Z., Deveraux, Q., Ellerby, L., Bredesen, D. and Reed, J. C. Bax directly induces release of cytochrome c from isolated mitochondria. *Proc. Natl. Acad. Sci. USA*, **95**, 4997–5002 (1998).

23) zou, H., Penzel, W. J., Liu, X., Lutschg, A. and Wang, X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. *Cell*, **90**, 405–413 (1997).

24) Li, P., Nijhawan, D., Buddhardo, I., Srivinasa, S. M., Ahmad, M., Alnemri, E. S. and Wang, X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. *Cell*, **91**, 479–489 (1997).

25) Esken, R., Antonsson, B., Osen-Sand, A., Montessuit, S., Richter, C., Sadoul, R., Mazzei, G., Nichols, A. and Martinon, J.-C. Bax-induced cytochrome c release from mitochondria is independent of the permeability transition pore but highly dependent on Mg2+ ions. *J. Cell Biol.*, **143**, 217–224 (1998).

26) Hu, Y., Benedict, M. A., Wu, D., Inohara, N. and Nunez, G. Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. *Proc. Natl. Acad. Sci. USA*, **95**, 4386–4391 (1998).

27) Sawa, H., Kobayashi, T., Mukai, K., Zhang, W. and Shiku, H. Bax overexpression enhances cytochrome c release from mitochondria and sensitizes KATOIII gastric cancer cells to chemotherapeutic agent-induced apoptosis. In *Int. J. Oncol.*, **16**, 745–749 (2000).

28) Guo, B., Yin, M.-B., Toth, K., Cao, S., Azrak, R. G. and Rustum, Y. M. Dimerization of mitochondrial Bax is associated with increased drug response in Bax-transfected A253 cells. *Oncol. Res.*, **11**, 91–99 (1999).

29) Strobelt, T., Kraeft, S.-K., Chen, L. B. and Cannistra, S. A. BAX expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for BAX during chemotherapy-induced cell death. *Cancer Res.*, **58**, 4776–4781 (1998).

30) Tai, Y.-T., Strobelt, T., KufE, D. and Cannistra, S. A. In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the Bax gene. *Cancer Res.*, **59**, 2121–2126 (1999).